Mechanism(s) of AR gene repression in prostate cancer

前列腺癌中 AR 基因抑制的机制

• 批准号: 7660395
• 负责人: BRYAN M WITTMANN
• 金额: $ 5.53万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7660395
• 关键词: Adverse effects; Androgen Receptor; Androgens; Cachexia; Chemicals; Clinical; Coupled; Development; Diagnosis; Family; Gene Activation; Genes; Genetic Transcription; Goals; Hand; Hypogonadism; Ligands; Maintenance; Malignant neoplasm of prostate; Mediating; Muscle; Nuclear Receptors; Pathogenesis; Pharmacology; Positioning Attribute; Process; Processed Genes; Prostate; Proteins; Receptor Gene; Receptor Signaling; Regulation; Role; Tissues; Work; activating transcription factor; cancer cell; cancer therapy; cofactor; comparative; gene repression; male; member; men; protein protein interaction; receptor; reproductive; selective androgen receptor modulator; small molecule; tissue processing; tool

DESCRIPTION (provided by applicant): Proposal Summary: The androgen receptor (AR), a member of the nuclear receptor family of ligand activated transcription factors, is a key regulator of the processes involved in the regulation of the male reproductive tract and in the development and maintenance of muscle. In addition however, inappropriate signaling by this receptor is implicated in the pathogenesis of prostate cancer (1,2). Thus, although androgens have clinical utility for the treatment of hypogonadism and cachexia, the untoward side effects with respect to prostate function have limited their use. This finding highlights the need for compounds whose androgenic actions are manifest in a tissue selective manner. Compounds of this class, now referred to as Selective Androgen Receptor Modulators (SARMs) were not comtemplated until recently. It is now considered that tissue/process selective androgens will be developed by exploiting the ability of ligands to facilitate the preferential interaction of the receptor with one cofactor over another (3,4). Whereas the majority of work in the field to date has focused on defining the roles of AR-cofactors in the process of.gene activation it has become clear to us that an examination of the roles of cofactors in negatively regulated gene transcription is lacking. Thus we have used (a) classical gene array studies to identify several hundred genes whose expression is downregulated by androgens in prostate cancer cells, (b) high throughput protein-protein interaction screens to isolate 265 proteins that interact with ligand activated AR and (c) chemical screens to define small molecules that permit the differential recruitment of cofactors to AR. With these key tools in hand we are in a good position to begin to define the cofactors that are important for AR- mediated target gene repression. To complete these goals, we propose the following specific aims: Aim 1: Definition of the mechanistic attributes of an AR-ligand that enable it to suppress gene transcription Aim 2: Identification of the cofactors required for AR-mediated gene repression Aim 3: Identification and comparative analysis of AR and cofactor recruitment to AR repressed genes Relevance: It is estimated in 2006, 234,460 men will be diagnosed with and 27,350 men will die from prostate cancer. Thus, due to the role of androgen receptor (AR) in prostate cancer, the identification of prostate cancer treatments and preventatives that can uncouple the positive effects from the negative effects of AR are of high necessity. The studies proposed within will assist in such discoveries.

摘要：雄激素受体（AR）是配体激活转录因子核受体家族的一员，是男性生殖道调节和肌肉发育和维持过程的关键调节剂。此外，该受体的不适当信号传导与前列腺癌的发病机制有关（1,2）。因此，尽管雄激素在治疗性腺功能减退和恶病质方面具有临床应用价值，但其对前列腺功能的不良副作用限制了雄激素的使用。这一发现强调了对雄激素作用以组织选择性方式表现的化合物的需求。这类化合物，现在被称为选择性雄激素受体调节剂（SARMs），直到最近才被考虑。现在认为，组织/过程选择性雄激素将通过利用配体的能力来促进受体与一个辅因子的优先相互作用而不是另一个（3,4）。到目前为止，该领域的大部分工作都集中在定义ar辅助因子在过程中的作用。基因激活它已经变得清楚，我们的检查的作用，在负调控基因转录的辅助因子是缺乏的。因此，我们使用了经典的基因阵列研究，在前列腺癌细胞中确定了几百个表达被雄激素下调的基因；(b)高通量蛋白质-蛋白质相互作用筛选，分离265种与配体激活的AR相互作用的蛋白质；(c)化学筛选，定义允许AR的辅因子差异募集的小分子。有了这些关键工具，我们就可以开始定义对AR介导的靶基因抑制很重要的辅因子。为了完成这些目标，我们提出以下具体目标：目标1：定义AR配体抑制基因转录的机制属性；目标2：确定AR介导的基因抑制所需的辅助因子；目标3：确定AR和AR抑制基因的辅助因子募集的鉴定和比较分析。相关性：据估计，2006年将有234,460名男性被诊断患有前列腺癌，27,350名男性将死于前列腺癌。因此，由于雄激素受体（雄激素受体，AR）在前列腺癌中的作用，寻找能够将AR的积极作用与消极作用分离开来的前列腺癌治疗和预防措施是非常必要的。书中提出的研究将有助于这些发现。